CTIM-25. ONCOLYTIC VIRUS FOR DIPG: THE CLINICAL EXPERIENCE WITH DNX-2401

Despite our increased understanding of Diffuse Intrinsic Pontine Glioma (DIPG) the outcome remains dismal. Recently we showed that the virus Delta-24-RGD (DNX-2401 in the clinic) was effective in preclinical models of DIPG and had the ability to trigger an antitumor immune response. These data allow...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Neuro Oncol
Päätekijät: M Alonso, Marta, Iñigo-Marco, Ignacio, Garcia-Moure, Marc, González-Huarriz, Marisol, Jones, Chris, MACKAY, Alan, Hulleman, Esther, Van der Lugt, Jasper, De Andrea, Carlos, Villalba, Maria, Hernandez, Ruben, Hervás, Sandra, Tamayo, Ibon, Lang, Frederick, Gomez-Manzano, Candelaria, Fueyo, Juan, Diez-Valle, Ricardo, de Larraya, Jaime Gállego-pérez, Tejada, Sonia
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2020
Aiheet:
Clinical Trials: Immunologic
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650359/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.159
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia